乳腺癌脑转移中 L1 细胞黏附分子和高内皮小静脉的免疫组化分析。
Immunohistochemical analysis of L1 cell adhesion molecule and high endothelial venules in breast cancer brain metastasis.
机构信息
Pathology Department, University Hospital of Saint-Etienne, France.
Pathology Department, University Hospital of Saint-Etienne, France.
出版信息
Pathol Res Pract. 2021 Jul;223:153484. doi: 10.1016/j.prp.2021.153484. Epub 2021 May 13.
BACKGROUND
The vasculature is a crucial factor in tumor development. Vascular co-option achieved by the L1 cell adhesion molecule (L1CAM) and lymphocyte recruitment inside tumors by high endothelial venules (HEVs) are important prognostic factors in primary breast cancer. Their status in breast cancer brain metastasis is unknown.
AIM OF THE STUDY
To explore the status of L1CAMs and HEVs in this tumor compartment.
MATERIAL AND METHODS
Thirty resected breast cancer brain metastases were immunohistochemically studied for L1CAM and MECA-79, an HEV marker. Clinicopathological factors were recorded.
RESULTS
Age at brain metastasis diagnosis ranged from 37 to 80 years (median 55). The time to brain metastasis development after primary tumor diagnosis ranged from 12 to 187 months (median 57). Median overall survival after brain metastasis diagnosis was 29 months. None of the tumors expressed the factors studied.
CONCLUSION
L1CAM and high endothelial venules are not found in breast cancer brain metastasis.
背景
脉管系统是肿瘤发展的关键因素。L1 细胞黏附分子（L1CAM）介导的血管募集和高内皮小静脉（HEVs）内的淋巴细胞募集是原发性乳腺癌的重要预后因素。它们在乳腺癌脑转移中的状态尚不清楚。
研究目的
探讨 L1CAM 和 HEVs 在该肿瘤部位的状态。
材料和方法
对 30 例切除的乳腺癌脑转移瘤进行 L1CAM 和 MECA-79（HEV 标志物）免疫组织化学研究。记录临床病理因素。
结果
脑转移诊断时的年龄为 37 至 80 岁（中位数为 55）。从原发性肿瘤诊断到脑转移发展的时间为 12 至 187 个月（中位数为 57）。脑转移诊断后总生存中位数为 29 个月。研究中未发现肿瘤表达这些因素。
结论
乳腺癌脑转移中未发现 L1CAM 和高内皮小静脉。
Zotero 插件